Skip to Content
Merck
All Photos(1)

Documents

371725

Sigma-Aldrich

GPR43 (FFA2) Agonist

The GPR43 (FFA2) Agonist controls the biological activity of GPR43. This small molecule/inhibitor is primarily used for Biochemicals applications.

Synonym(s):

GPR43 (FFA2) Agonist, (S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C21H21ClN2OS
CAS Number:
Molecular Weight:
384.92
UNSPSC Code:
51111800
NACRES:
NA.77

Quality Level

Assay

>98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

white

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

2-8°C

General description

A phenylacetamide compound that acts as an allosteric agonist of FFA2 (GPR43), demonstrating a left-shifted acetate dose response (IC50 = 0.7 µM) and 111% efficacy relative to acetate in hFFA2 forskolin-induced cAMP assays.

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Wang, Y., et al. 2009. Bioorg. Med. Chem. Lett.20, 493.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sandra M Holmberg et al.
Nature communications, 15(1), 3502-3502 (2024-04-26)
Beneficial gut bacteria are indispensable for developing colonic mucus and fully establishing its protective function against intestinal microorganisms. Low-fiber diet consumption alters the gut bacterial configuration and disturbs this microbe-mucus interaction, but the specific bacteria and microbial metabolites responsible for
Anne Ørgaard et al.
Islets, 11(5), 103-111 (2019-08-31)
The intestinal microbiota has been demonstrated to influence host metabolism, and has been proposed to affect the development of obesity and type 2 diabetes (T2D), possibly through short-chain fatty acids (SCFAs) produced by fermentation of dietary fiber. There are some
Signe Schultz Pedersen et al.
The FEBS journal, 291(3), 566-583 (2023-11-21)
Butyrate, a gut microbial metabolite, has beneficial effects on glucose homeostasis and has become an attractive drug candidate for type 2 diabetes (T2D). Recently, we showed that butyrate protects pancreatic beta cells against cytokine-induced dysfunction. In this study, we explored
Bandik Föh et al.
PloS one, 17(3), e0266071-e0266071 (2022-03-26)
The microbially-derived short-chain fatty acid butyrate is a central inhibitor of inflammatory innate and adaptive immune responses. Emerging evidence suggests that butyrate induces differentiation of IL-10-producing (IL-10+) regulatory B cells. However, the underlying mechanisms of butyrate-driven modulation of B cell
Mona Farhadipour et al.
iScience, 26(12), 108517-108517 (2023-12-21)
Stem cells are a keystone of intestinal homeostasis, but their function could be shifted during energy imbalance or by crosstalk with microbial metabolites in the stem cell niche. This study reports the effect of obesity and microbiota-derived short-chain fatty acids

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service